INTRODUCTION
Osteoarthritis is characterized by the degeneration of the articular cartilage and is treated by PCPs, rheumatologists and orthopedic surgeons. It
is the most prevalent form of arthritis, affecting approx. 10% of the population, equating to a patient population of over 73 million people in the
seven major pharmaceutical markets.
SCOPE OF THE REPORT
- COX-2 inhibitor focused analysis of data into prescribing patterns, switching and side effects from treating physicians and opinion leaders
- Country specific drug-treated population is used to provide patient numbers for each drug class with each of the most commonly used drugs listed
- Prescribing and influencing factors cited by the physicians surveyed for five classes of drug used in mono- and combination therapy
- Clinical trial design with an in-depth case study of Prexige and reimbursement issues for each of the target markets
REPORT HIGHLIGHTS
COX-2 inhibitors are used in 34% of the total OA population. Uptake varies over the seven different markets with 40% of severe patients currently
prescribed them in the US and only 26% of severe patients receiving them in the UK. Use increases with disease severity across all markets. Traditional
NSAID and COX-2 use is strongly influenced by switching trends between the two. Variation in prescribing rates is due to a number of influences
including, DTC advertising, the high prices of COX-2s and the ability of different healthcare systems to deal with them. Clinical trial design is
critical, as shown by the FDA decision to delay the approval of Prexige. This is attributed to a number of factors including trial duration, choice of
comparator, the VIGOR results or pharmacology issues in the US. To gain market share it needs to supplant Pfizer's Celebrex and Bextra as well as
Merck's Vioxx and Arcoxia.
KEY REASONS TO BUY THIS REPORT
- Use prescription rates to predict product sales across the seven major markets
- Target specific geographical areas and disease severities to ensure maximum product uptake
- Plan clinical trials and provide useful marketing data using the trial analysis and suggestions for improvement in this report
| 
View Cart
